These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 24150927)
1. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. Das S; Armstrong J; Mathews D; Li J; Edeki T J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval. Riccobene TA; Rekeda L; Rank D; Llorens L Antimicrob Agents Chemother; 2013 Apr; 57(4):1777-83. PubMed ID: 23357764 [TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Riccobene TA; Su SF; Rank D Antimicrob Agents Chemother; 2013 Mar; 57(3):1496-504. PubMed ID: 23295928 [TBL] [Abstract][Full Text] [Related]
4. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737 [TBL] [Abstract][Full Text] [Related]
5. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. Lucasti C; Popescu I; Ramesh MK; Lipka J; Sable C J Antimicrob Chemother; 2013 May; 68(5):1183-92. PubMed ID: 23391714 [TBL] [Abstract][Full Text] [Related]
7. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264 [TBL] [Abstract][Full Text] [Related]
8. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361 [TBL] [Abstract][Full Text] [Related]
9. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study. de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315 [TBL] [Abstract][Full Text] [Related]
11. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Nicolau DP; Siew L; Armstrong J; Li J; Edeki T; Learoyd M; Das S J Antimicrob Chemother; 2015 Oct; 70(10):2862-9. PubMed ID: 26133566 [TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan H; Rangaraju M; Tarral A Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217 [TBL] [Abstract][Full Text] [Related]
13. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers. Kori S; Kellerman DJ; Voloshko P; Haugen G Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853 [TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous zanamivir on cardiac repolarization. Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Gottfridsson C; Carlson G; Lappalainen J; Sostek M Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects. Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934 [TBL] [Abstract][Full Text] [Related]
17. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study. Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423 [TBL] [Abstract][Full Text] [Related]
18. A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. Gall J; Choi T; Riddle V; Van Wart S; Gibbons JA; Seroogy J Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1032-1041. PubMed ID: 30650259 [TBL] [Abstract][Full Text] [Related]
19. Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants. Suico JG; Friedrich S; Krueger KA; Zhang W J Cardiovasc Pharmacol Ther; 2014 May; 19(3):283-9. PubMed ID: 24271137 [TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial. Bradley JS; Roilides E; Broadhurst H; Cheng K; Huang LM; MasCasullo V; Newell P; Stone GG; Tawadrous M; Wajsbrot D; Yates K; Gardner A Pediatr Infect Dis J; 2019 Sep; 38(9):920-928. PubMed ID: 31335570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]